EUCTR2011-005254-53-DE进行中（未招募）不适用
A double-blind, randomised, placebo controlled, sequential ascending dose study, to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single intra-articular doses of fasitibant in patients with symptomatic osteoarthritis of the knee. - ALBATROSS-2
Menarini Ricerche S.p.A0 个研究点目标入组 60 人开始时间: 2012年2月14日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent.
- •2.Male or female patients = 30 years old and a BMI < 30 kg/m².
- •3.Women of childbearing potential are eligible to participate in the study if their pregnancy test is negative at screening, they are not nursing, and they use an effective method of contraception.
- •4. Symptomatic primary or secondary knee osteoarthritis for which IA treatment is indicated.
- •5. Pain score >5 points assigned to the index knee at WOMAC NR 3.1-A1.
- •6. Pain score >12 points assigned to the index knee at WOMAC NR 3.1 A subscore. 7. Pain in the index knee on at least 50% of the days in the month preceding the screening.
- •8. Minimum flexion of 90 degrees in both knees.
- •9. Ability to perform the 15 m walk test without the support of crutches or other assistive devices.
- •10. Willingness to discontinue all pain or OA medication.
- •11. Willingness to refrain from paracetamol use 48 hours prior to each study visit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1. Inability to personally provide written informed consent.
- •2. Inability to understand or collaborate throughout the study.
- •3. Patients who participated in another clinical trial within 30 days prior randomisation.
- •4. Patients with severe OA of the knee.
- •5. Knee condition representing an indication for surgery .
- •6. Inflammatory or crystal arthropathies.
- •7. Patients with acute fractures, severe loss of bone density, bone necrosis.
- •8. Patients with isolated patella-femoral syndrome or chondromalacia.
- •9. Patients with OA predominant in the lateral compartment.
- •10. Patients with any other clinically significant and unstable disease or condition interfering with the evaluation of the safety of study treatment.
- •11. Major injury or surgery to the index knee within the previous 12 months prior to screening.
- •12. Severe hip OA ipsilateral to index knee.
- •13. Any pain >3 points in the numerical rating (NR) scale (0-10) that could interfere with the assessment of the index knee pain.
- •14. Any pharmacological or non-pharmacological treatment started or changed during 4 weeks prior to randomisation.
- •15. Use of systemic or topical corticosteroids >10 mg prednisolone equivalent.
- •16. Use of any pain or OA medication.
- •17. Any acute or newly diagnosed disease/condition requiring treatment.
- •18. Any unstable chronic disease/condition requiring treatment modification.
- •19. History of hypersensitivity to drugs including paracetamol.
- •20. Patient with known hypersensitivity to hyaluronate preparations.
- •21. Patients with any of the following
- •a) clinically relevant cardiovascular, pulmonary, gastrointestinal, haematological, neurologic-psychiatric or infectious diseases.
- •b) clinically relevant abnormal safety laboratory test result and/or clinically relevant abnormalities in vital signs and/or ECG parameters at screening (Visit 1) and/or prior to dose administration (Visit 2).
- •22. Patients with liver disease
- •23. Patients with moderate or severe renal insufficiency (Creatinie Clearence [CrCl according to Cockgroft-Gault formula] < 60 mL/min).
- •24. Any sign of significant inflammation or infection.
- •25. Any skin disorder or infection overlying the index knee.
- •26. Previous infection of the index knee.
- •27. Any IA or local peri-articular punction, injection, or surgery to the index knee during the 3 months prior to screening.
- •28. Patients with bleeding diathesis or on therapy with anticoagulants.
- •29. Significant peri-articular calcification.
- •30. Previous ligament reconstruction at the index knee.
研究者
相似试验
招募中
不适用
A double-blind, randomized, placebo-controlled, sequential ascending single-dose study to evaluate the pharmacokinetic and tolerability profiles of teriflunomide in healthy Korean subjectsDiseases of the nervous systemKCT0000539Sanofi-Aventis Korea36
进行中（未招募）
1 期
A double-blind, randomised, placebo controlled, single dose, two-period crossover study to investigate the therapeutic potential of the TRPV1 antagonist SB-705498 in treatment of subjects with rectal hypersensitivity including irritable bowel syndrome.EUCTR2006-002632-21-GBGlaxoSmithKline Research & Development
进行中（未招募）
1 期
A clinical trial with blinded patients and personnel investigating the safety and preliminary dose-finding effects of the medicinal product LL-37 in hard-to-heal leg ulcers in comparison with an inactive substance (placebo)EUCTR2012-002100-41-SEipopeptide AB35
撤回
不适用
A randomized, double-blind, placebo-controlled, serial-cohort, single ascending dose of Xen2174 with bupivacaine interaction study administered intrathecally in healthy volunteers.pain after surgeryPost operative pain10007867NL-OMON35341Xenome Ltd.44
已完成
不适用
A randomized, double-blind, placebo-controlled, serial-cohort, single ascending dose of Xen2174 PK/PD study administered intrathecally in healthy volunteers.10007867pain after surgeryPost operative painNL-OMON35658Xenome Ltd.32